https://orcid.org/0000-0001-7746-5445
References
- Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005;62:258–264.
- Siegal D, Keller A, Xu W, et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007;13:1369–1379.
- Barba P, Piñana JL, Valcárcel D, et al. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1439–1446.
- Delios AM, Rosenblum M, Jakubowski AA, et al. Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease. J Neurooncol. 2012;110:251–256.
- Saito N, Tanaka T, Matsuda S, et al. A case of inflammatory demyelinative myelopathy after bone marrow transplantation. Rinsho Shinkeigaku. 2000;40:556–560.
- Hirano M, Jimbo K, Ogawa M, et al. Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation. Bone Marrow Transplant. 2018;53:1470–1473.
- Lorenzoni PJ, Scola RH, Carsten ALM, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: case report. Arq Neuropsiquiatr. 2007;65:700–704.
- Eliashiv S, Brenner T, Abramsky O, et al. Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation. Bone Marrow Transplant. 1991;8:315–317.
- Stefanou MI, Bischof F. Central and peripheral nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation. J Neuroimmunol. 2017;307:74–81.
- Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
- O’Brien K, Gran B, Rostami A. T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy. 2010;2:99–115.
- Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9:409–416.
- Flach A-C, Litke T, Strauss J, et al. Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proc Natl Acad Sci U S A. 2016;113:3323–3328.
- Hauser SL, Waubant E, Arnold DL, et al. HERMES trial group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
- Jelcic I, Al Nimer F, Wang J, et al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell. 2018;175(1):85–100.
- Bowen L, Nath A, Smith B. CNS immune reconstitution inflammatory syndrome. Handb Clin Neurol. 2018;152:167–176.
- Mutnal MB, Schachtele SJ, Hu S, et al. T-cell reconstitution during murine acquired immunodeficiency syndrome (MAIDS) produces neuroinflammation and mortality in animals harboring opportunistic viral brain infection. J Neuroinflammation. 2013;10:98.
- Zhang X-H, Zhao X, Wang -C-C, et al. IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. Ann Hematol. 2018 Aug;97(8):1399–1406.
- Grauer O, Wolff D, Bertz H, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the consensus conference on clinical practice in chronic graft-versus-host disease. Brain. 2010;133(10):2852–2865.
- Ruggiu M, Cuccuini W, Mokhtari K, et al. Case report: central nervous system involvement of human graft versus host disease: report of 7 cases and a review of literature. Medicine (Baltimore). 2017;96(42):e8303.
- Bittner S, Ruck T, Wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10:51–66.